{"ok":true,"data":{"subject":{"kind":"trial","nctId":"NCT07604233","title":"Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML","sponsor":"M.D. Anderson Cancer Center","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","indication":null,"disease":"myeloid leukemia"},"rows":[{"n":1,"question":"Is the biology right?","flags":[{"id":"somatic_driver","label":"Somatic driver evidence","value":"no","detail":"None of BCL2, ABL1, BCR, CD3E, CD3G, CD3D has somatic-mutation evidence in myeloid leukemia","rule":"Open Targets has somatic-mutation evidence for the target in this cancer","source":{"label":"Open Targets: BCL2 in myeloid leukemia","url":"https://platform.opentargets.org/evidence/ENSG00000171791/MONDO_0004643","date":"2026-11-11T17:23:17.774Z"},"context":[]},{"id":"human_genetic","label":"Human genetic evidence","value":"no","detail":"No germline or somatic evidence for BCL2, ABL1, BCR, CD3E, CD3G, CD3D in myeloid leukemia","rule":"Any germline or somatic human genetic evidence for the target in this cancer, counted apart from animal-model and literature evidence","source":{"label":"Open Targets: BCL2 in myeloid leukemia","url":"https://platform.opentargets.org/evidence/ENSG00000171791/MONDO_0004643","date":"2026-11-11T17:23:17.774Z"},"context":[]},{"id":"pediatric_target","label":"Pediatric target","value":"yes","detail":"ABL1 on the FDA list","rule":"Target is on FDA's Pediatric Molecular Target List (relevant targets); membership alone neither requires nor waives a study","source":{"label":"FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01))","url":"https://www.fda.gov/media/191157/download?attachment","date":"2026-11-11T07:05:03Z"},"context":[]},{"id":"haematologic","label":"Haematologic cancer","value":"yes","detail":"Haematologic","rule":"From the indication, or the registry conditions when no indication matches","source":{"label":"ClinicalTrials.gov NCT07604233","url":"https://clinicaltrials.gov/study/NCT07604233","date":"2026-11-11T17:23:17.774Z"},"context":[{"figure":"Likelihood of approval from phase 1: 7.5% haematologic vs 4.6% solid","dataset":"BIO / Informa / QLS 2021","years":"2011–2020","caveat":"Population-level, not a prediction."}]}],"facts":[{"label":"Background therapy","text":"Fludarabine, Cytarabine, Idarubicin, Filgrastim: standard agents, not counted in these flags."},{"label":"BCL2 (via Venetoclax)","text":"Evidence types in myeloid leukemia: literature, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc.","source":{"label":"Open Targets: BCL2 in myeloid leukemia","url":"https://platform.opentargets.org/evidence/ENSG00000171791/MONDO_0004643","date":"2026-11-11T17:23:17.774Z"}},{"label":"ABL1 (via Asciminib)","text":"Evidence types in myeloid leukemia: literature, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc.","source":{"label":"Open Targets: ABL1 in myeloid leukemia","url":"https://platform.opentargets.org/evidence/ENSG00000097007/MONDO_0004643","date":"2026-11-11T17:23:17.774Z"}},{"label":"BCR (via Asciminib)","text":"Evidence types in myeloid leukemia: literature, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc.","source":{"label":"Open Targets: BCR in myeloid leukemia","url":"https://platform.opentargets.org/evidence/ENSG00000186716/MONDO_0004643","date":"2026-11-11T17:23:17.774Z"}},{"label":"CD3E (via Blinatumomab)","text":"Evidence types in myeloid leukemia: literature; literature listed separately from human genetics. Datasources: europepmc.","source":{"label":"Open Targets: CD3E in myeloid leukemia","url":"https://platform.opentargets.org/evidence/ENSG00000198851/MONDO_0004643","date":"2026-11-11T17:23:17.774Z"}},{"label":"CD3G (via Blinatumomab)","text":"Open Targets has no association between CD3G and myeloid leukemia.","source":{"label":"Open Targets: CD3G in myeloid leukemia","url":"https://platform.opentargets.org/evidence/ENSG00000160654/MONDO_0004643","date":"2026-11-11T17:23:17.774Z"}},{"label":"CD3D (via Blinatumomab)","text":"Open Targets has no association between CD3D and myeloid leukemia.","source":{"label":"Open Targets: CD3D in myeloid leukemia","url":"https://platform.opentargets.org/evidence/ENSG00000167286/MONDO_0004643","date":"2026-11-11T17:23:17.774Z"}}],"pending":[{"what":"Normal-tissue expression in vital organs","source":"Human Protein Atlas (ticket 36)"},{"what":"Pan-essential in cell lines","source":"DepMap (ticket 36)"},{"what":"Approved drug on this target","source":"Drugs@FDA (ticket 30)"}]},{"n":2,"question":"Can the result be trusted?","flags":[{"id":"randomised","label":"Randomised","value":"no","detail":"Non-randomised","rule":"Registry allocation field","source":{"label":"ClinicalTrials.gov NCT07604233","url":"https://clinicaltrials.gov/study/NCT07604233","date":"2026-11-11T17:23:17.774Z"},"context":[]},{"id":"small_denominator","label":"Small denominator","value":"no","detail":"30 planned; each patient moves a rate by 100 ÷ 30 = 3.3 points","rule":"Enrolment under 30; the arithmetic is shown, not a benchmark","source":{"label":"ClinicalTrials.gov NCT07604233","url":"https://clinicaltrials.gov/study/NCT07604233","date":"2026-11-11T17:23:17.774Z"},"context":[]},{"id":"primary_os","label":"Primary endpoint is overall survival","value":"no","detail":"Safety and Adverse Events (AEs)","rule":"A registered primary outcome measure names overall survival","source":{"label":"ClinicalTrials.gov NCT07604233","url":"https://clinicaltrials.gov/study/NCT07604233","date":"2026-11-11T17:23:17.774Z"},"context":[{"figure":"Non-OS primary endpoint: odds ratio 2.79 for a positive phase 3","dataset":"Otsuka 2021, 400 phase 3 oncology trials","years":"to 2020","caveat":"Shown with the next figure: a surrogate is easier to hit, and often a weak guide to survival."},{"figure":"52% of surrogate-to-OS correlations are low","dataset":"Prasad 2015","years":"published to 2014","caveat":"Shown with the figure above."}]},{"id":"results_overdue","label":"Results overdue","value":"no","detail":"Primary completion expected 2031-06-03; not yet due","rule":"Primary completion (actual) more than 12 months ago and no results posted to the registry","source":{"label":"ClinicalTrials.gov NCT07604233","url":"https://clinicaltrials.gov/study/NCT07604233","date":"2026-11-11T17:23:17.774Z"},"context":[]}],"facts":[],"pending":[{"what":"Treated and evaluable counts, assessor, confirmed response, follow-up and data cutoff","source":"Readout extraction (ticket 32)"},{"what":"Primary endpoint changed between registry versions","source":"Registry versions in the store (ticket 32)"}]},{"n":3,"question":"What must it beat?","flags":[],"facts":[],"pending":[{"what":"Control-arm result and approved therapies for the same segment, with label links","source":"Drugs@FDA, FDA labels and readouts (tickets 30, 32)"}]},{"n":4,"question":"Too crowded, or too late?","flags":[],"facts":[{"label":"Stopped on this target","text":"147 terminated, withdrawn or suspended trials of drugs against BCL2; 9 give no reason. Reasons are quoted as the registry gives them on the target page.","source":{"label":"BCL2: what already stopped","url":"/target/ENSG00000171791#stopped","date":"2026-11-11T17:23:17.792Z"}}],"pending":[{"what":"Programs on the target by phase and months behind the leader","source":"Programs and Drugs@FDA (ticket 33)"}]},{"n":5,"question":"Can it be approved, and stay approved?","flags":[{"id":"single_country","label":"Single-country","value":"yes","detail":"The only site is in United States","rule":"All listed sites are in one country; the share of US sites is shown","source":{"label":"ClinicalTrials.gov NCT07604233","url":"https://clinicaltrials.gov/study/NCT07604233?tab=locations","date":"2026-11-11T17:23:17.774Z"},"context":[]},{"id":"eu_pip","label":"EU paediatric investigation plan","value":"yes","detail":"EMA/PE/0000221213 (blinatumomab, Treatment of B-lymphoblastic leukaemia/lymphoma): PM: decision on the application for modification of an agreed PIP, 3 Jan 2025; EMA/PE/0000182075 (venetoclax, Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue;Treatment of solid malignant tumours): PM: decision on the application for modification of an agreed PIP, 3 Jan 2025; EMEA-000574-PIP02-12-M04 (blinatumomab, Treatment of acute lymphoblastic leukaemia): PM: decision on the application for modification of an agreed PIP, 27 Oct 2023; compliance positive 23 Feb 2024; EMEA-002347-PIP01-18 (asciminib, Treatment of chronic myeloid leukaemia): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), 29 Jan 2020","rule":"An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name","source":{"label":"EMA data download (dated snapshot)","url":"https://www.ema.europa.eu/en/documents/report/medicines-output-paediatric_investigation_plans-output-json-report_en.json","date":"2026-11-11T09:12:26Z"},"context":[]},{"id":"eu_orphan","label":"EU orphan designation","value":"yes","detail":"EU/3/17/1954 withdrawn 12 Dec 2017: Treatment of mantle cell lymphoma; EU/3/16/1766 withdrawn 14 Oct 2016: Treatment of diffuse large B-cell lymphoma; EU/3/20/2261 positive 24 Mar 2020: Treatment of chronic myeloid leukaemia; EU/3/03/176 withdrawn 1 Dec 2003: Treatment of chronic lymphocytic leukaemia; +5 more","rule":"An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status","source":{"label":"EMA data download (dated snapshot)","url":"https://www.ema.europa.eu/en/documents/report/medicines-output-orphan_designations-json-report_en.json","date":"2026-11-11T09:12:26Z"},"context":[]},{"id":"eu_authorised","label":"Authorised in the EU","value":"yes","detail":"Blincyto: authorised since 23 Nov 2015, orphan medicine; Scemblix: authorised since 25 Aug 2022, orphan medicine; Venclyxto: authorised since 4 Dec 2016","rule":"An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file","source":{"label":"EMA data download (dated snapshot)","url":"https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json","date":"2026-11-11T09:12:26Z"},"context":[]},{"id":"fda_orphan","label":"FDA orphan designation","value":"not published","detail":"FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the link","rule":"Would be: an FDA orphan designation names the drug","source":{"label":"FDA orphan designations search","url":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/","date":""},"context":[]},{"id":"fda_ped_approval","label":"FDA pediatric oncology approval","value":"yes","detail":"Blinatumomab [Blincyto], 14 Jun 2024: Treatment of CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy in adult and pediatric patients one month and older; Blinatumomab [Blincyto], 29 Mar 2018: Treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adult and pediatric patients one month and older; Blinatumomab [Blincyto], 11 Jul 2017: Treatment of relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older","rule":"FDA's Pediatric Oncology Drug Approvals table names the drug","source":{"label":"FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03)","url":"https://www.fda.gov/about-fda/oncology-center-excellence/pediatric-oncology-drug-approvals","date":"2026-11-11T17:23:17.804Z"},"context":[]},{"id":"studies_under_18","label":"Registered studies open to children","value":"yes","detail":"173 interventional studies of Venetoclax, Asciminib, Blinatumomab include patients under 18; 131 are recruiting, not yet recruiting or active","rule":"The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age","source":{"label":"ClinicalTrials.gov search","url":"https://clinicaltrials.gov/search?intr=%22Venetoclax%22+OR+%22Asciminib%22+OR+%22Blinatumomab%22&aggFilters=ages%3Achild%2CstudyType%3Aint","date":"2026-11-11T17:23:17.814Z"},"context":[]}],"facts":[{"label":"Caveat","text":"Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where the sites are is a fact about the record, not a judgement of its quality."},{"label":"Rare pediatric disease voucher","text":"FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news.","source":{"label":"FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs","url":"https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/rare-pediatric-disease-designation-and-priority-review-voucher-programs","date":"2026-11-11"}}],"pending":[{"what":"Precedent approvals for target, modality and endpoint; accelerated-approval status","source":"Drugs@FDA and FDA accelerated-approval tables (ticket 30)"}]},{"n":6,"question":"Can the sponsor finish?","flags":[],"facts":[{"label":"Sponsor","text":"M.D. Anderson Cancer Center (academic or other)","source":{"label":"ClinicalTrials.gov NCT07604233","url":"https://clinicaltrials.gov/study/NCT07604233","date":"2026-11-11T17:23:17.774Z"}},{"label":"principal investigator","text":"Fadi Haddad, MD, UT MD Anderson","source":{"label":"Person page","url":"/person/Fadi%20Haddad%2C%20MD","date":"2026-11-11T17:23:17.774Z"}}],"pending":[{"what":"Filed cash, quarterly spend and the runway arithmetic","source":"SEC XBRL company facts (ticket 37)"},{"what":"Sponsor's completed vs stopped oncology trials and results-reporting record","source":"Registry, by company (ticket 37)"}]}],"limits":"Public records cannot show: sales forecasts; a probability of success for this asset; full deal terms and net prices; FDA designations and action dates before approval (shown only as company-reported); clinical holds unless the company disclosed them; manufacturing; patents on unapproved drugs; whether preclinical findings have been replicated.","sources":[{"label":"ClinicalTrials.gov NCT07604233","url":"https://clinicaltrials.gov/study/NCT07604233","date":"2026-11-11T17:23:17.774Z"},{"label":"Open Targets Platform","url":"https://platform.opentargets.org","date":"2026-11-11T17:23:17.774Z"},{"label":"FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01))","url":"https://www.fda.gov/media/191157/download?attachment","date":"2026-11-11T07:05:03Z"}]},"source":"ClinicalTrials.gov + Open Targets","fetchedAt":"2026-11-11T17:23:17.773Z"}